U.S. Markets close in 6 hrs 5 mins

Weekly CEO Buys Highlight

According to GuruFocus Insider Data, these are the largest CEO buys during the past week.

OPKO Health

OPKO Health Inc. (NASDAQ:OPK) CEO, Chairman and 10% Owner Phillip Frost bought 350,000 shares on Nov. 6 at a price of $1.49. The price of the stock has decreased by 1.34% since then.

cf7eb9187d995ac82c806e0a3e67c231.png


OPKO Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. The company's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. OPKO Health also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing.

The company has a market cap of $978.43 million. Its shares traded at $1.47 as of Nov. 8. Net loss for the three months ended September 30, 2019 was $62 million compared with a net loss of $27.7 million for the comparable period of 2018.

Frost bought 2,000,000 shares on Oct. 25 at a price of $1.5; 200,000 shares on Oct. 29 at a price of $1.47; 200,000 shares on Oct. 30 at a price of $1.44; and 50,000 shares on Oct. 31 at a price of $1.43. Since then, the price of the stock has increased by 2.8%.

The company's Executive Vice President - Administration, Steven D. Rubin, bought 15,000 shares on Oct. 25 at a price of $1.5. The price of the stock has decreased by 2% since then.

Vice Chairman and Chief Technical Officer Jane Hsiao bought 400,000 shares on Oct. 25 at a price of $1.5. Since then, the price of the stock has decreased by 2%.

Director Richard C. Pfenniger Jr. bought 25,000 shares on Oct. 25 at a price of $1.45. The price of the stock has increased by 1.38% since then.

McDonald's Corp.

McDonald's Corp. (NYSE:MCD) President and CEO Christopher J. Kempczinski bought 2,580 shares on Nov. 6 at a price of $193.81. Since then, the price of the stock has decreased by 0.1%.

9103db1273970931c4d5e60b5e8090ce.png

McDonald's generates revenue through company-owned restaurants, franchise royalties and licensing pacts. Restaurants offer a uniform value-priced menu with some regional variations. As of December 2017, there were 37,200 locations in 120 countries: 34,100 franchisee/affiliate units and 3,100 company units. In 2015, Easterbrook introduced a four-pillar approach to systemwide operational improvements emphasizing organizational accountability, customer centricity, progress over perfection and process simplification.

The company has a market cap of $145.81 billion. Its shares traded at $193.61 with a price-earnings ratio of 25.41 as of Nov. 8. Net income for the third quarter of 2019 was $1.61 billion compared to $1.64 billion for the prior-year quarter.

Director John J. Mulligan bought 1,300 shares on Nov. 6 at a price of $193.46. The price of the stock has increased by 0.08% since then.

Stewart Information Services

Stewart Information Services Corp. (NYSE:STC) CEO Frederick H. Eppinger bought 11,316 shares on Nov. 7 at a price of $40.61. Since then, the price of the stock has increased by 3.5%.

e033643c88b3f03a77672d24a6bfeec5.png

Stewart Information Services is a provider of real estate services. The company offers residential and commercial title insurance and closing and settlement services to the mortgage industry. In its title insurance services business segment, the company offers searching, examining, closing and insuring services of the title of real property. The mortgage services business segment provides mortgage origination support, default and real estate owned services, loan review and audit services through Stewart Lender Services and PropertyInfo's Stewart Government Services. Stewart operates primarily in the United States.

The company has a market cap of $996.62 million. Its shares traded at $42.03 with a price-earnings ratio of 11.09 as of Nov. 8. Third-quarter net income for 2019 was $66.1 million compared to third quarter 2018 net income of $17.6 million.

Director Glenn C. Christenson sold 15,000 shares on Oct. 29 at a price of $40.57. The price of the stock has increased by 3.6% since then.

Virtu Financial

Virtu Financial Inc. (NASDAQ:VIRT) CEO Douglas A. Cifu bought 20,000 shares on Nov. 7 at a price of $16.24. Since then, the price of the stock has decreased by 0.06%.

41694bb5111ccffe859cbf0d174abc2b.png

Virtu Financial is a leading technology-enabled market maker and liquidity provider to the global financial markets. It maintains a technology platform that provides quotations to buyers and sellers in equities, global currencies, fixed income, global commodities (including energy and metals), options and other securities. The group generates revenue by buying and selling large volumes of securities and other financial instruments and earning small bid/ask spreads. In addition, it also earns revenues from interest and dividend income, as well as through the sale of licensed technology and related services.

The company has a market cap of $3.09 billion. Its shares traded at $16.23 with a price-earnings ratio of 52.19 as of Nov. 8. Net loss for the third quarter of 2019 was $5.18 million compared to a loss of $15.61 million for the prior-year quarter.

RAPT Therapeutics

RAPT Therapeutics Inc. (NASDAQ:RAPT) President and CEO Brian Russell Wong bought 25,000 shares on Nov. 4 at a price of $12.00. The price of the stock has increased by 134.17% since then.

036cd68e0de944d9e50b6695ee2bf6a6.png

RAPT Therapeutics, a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidates are FLX475 for the treatment of a range of tumors and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

The company has a market cap of $597.97 million. Its shares traded at $28.10 as of Nov. 8. On Oct. 30, 2019, the company announced the pricing of its initial public offering of 3,000,000 shares of common stock at a public offering price of $12.00 per share.

10% Owner Column Group II LP bought 625,000 shares on Nov. 4 at the IPO price of $12. The price of the stock has increased by 134.17% since then.

Director Wendye Robbins bought 1,600 shares on Nov. 4 at a price of $12. The price of the stock has increased by 134.17% since then.

Director and 10% Owner David V. Goeddel bought 625,000 shares on Nov. 4 at a price of $12. The price of the stock has increased by 134.17% since then.

Director William J. Rieflin bought 8,000 shares on Nov. 4 at a price of $12. The price of the stock has increased by 134.17% since then.

For the complete list of stocks bought by their company CEOs, go to: CEO Buys.

Disclosure: I do not own stock in any of the companies mentioned in the article.

Read more here:



Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.